Neurodegenerative diseases (NDDs) present a great societal and economic burden and have generated a huge unmet medical need. NDDs are characterized by deterioration of neurons that lead to brain dysfunction, resulting in impairment of motor movement and/or cognitive abilities. Affecting primarily the growing aging population, these disorders are increasing in prevalence and significantly raising heatlhcare costs in the Western world.
Innovative therapeutic approaches that provide safe and effective treaments have a multi-billion dollar potential. According to a recent report, the U.S. constitutes the world's largest market for NDD products, worth nearly $2.3 billion in 2004, or 40% of global sales. This figure is expected to rise to over $10 billion by 2013. According to the World Health Organization, NDDs will become the world's second leading cause of death by 2040, overtaking cancer.
Addressable Market
At this stage, it is anticipated that BrainStorm‘s therapy will be applicable to all diagnosed cases of the target neurodegenerative diseases. However, due to the likely cost and potential concerns regarding a surgical procedure, it is currently assumed that between 10% and 50% of sufferers represent the true addressable market.
PD is a long-term condition, effecting sufferers for an average of 15 years. Annual treatment costs are estimated at $18,000. Therefore, total costs per patient are up to $270,000. For ALS patients, annual treatment costs are higher.
|
|
PD |
ALS |
MS |
Total |
|
Number of Sufferers |
4,000,000 |
100,000 |
700,000 |
4,800,000
|
|
Total Market Value |
$20 billion
|
$2.5 billion
|
$3.5 billion
|
$26 billion
|
The procedure will provide compelling medical and economic advantages for patients, medical practitioners and insurance/healthcare providers. Patients will enjoy a rapid recovery and much enhanced quality of life. The principle value proposition is massive savings in treatment and care costs.
Market
